Current means for identifying the latent stage of a neurodegenerative process
A characteristic feature of neurodegenerative diseases is thepresence of a long-term latent stage, while manifestation ofsymptoms occurs after 4060% cells loss in vulnerable neuronpopulations. Therefore, potential for neuroprotection is maximaljust at the latent stage of the process. In this paper,...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Research Center of Neurology
2017-02-01
|
| Series: | Анналы клинической и экспериментальной неврологии |
| Subjects: | |
| Online Access: | https://annaly-nevrologii.com/journal/pathID/article/viewFile/236/72 |
| _version_ | 1811244282335461376 |
|---|---|
| author | S. N. Illarioshkin A. G. Vlassenko E. Yu. Fedotova |
| author_facet | S. N. Illarioshkin A. G. Vlassenko E. Yu. Fedotova |
| author_sort | S. N. Illarioshkin |
| collection | DOAJ |
| description | A characteristic feature of neurodegenerative diseases is thepresence of a long-term latent stage, while manifestation ofsymptoms occurs after 4060% cells loss in vulnerable neuronpopulations. Therefore, potential for neuroprotection is maximaljust at the latent stage of the process. In this paper, currenttechnologies of presymptomatic diagnosis of the two most commonneurodegenerative disorders, Alzheimers and Parkinsons
disease, are presented. On the basis of our own experience anddata from the literature it is shown that neuroimaging methods(identification of beta-amyloid in the brain, or phenomenon ofhyperechogenecity of the s.nigra, etc) in combination with anumber of neurophysiological and molecular/pathobiochemicaltests are principal in revealing persons with high risk of these disorders.Validation of biomarkers under discussion and their integration
into uniform diagnostic screening algorithms is at presentone of the most actual fields of neurology. |
| first_indexed | 2024-04-12T14:22:07Z |
| format | Article |
| id | doaj.art-9f70fc0d48ef4d44961ffd32006ad18f |
| institution | Directory Open Access Journal |
| issn | 2075-5473 2409-2533 |
| language | English |
| last_indexed | 2024-04-12T14:22:07Z |
| publishDate | 2017-02-01 |
| publisher | Research Center of Neurology |
| record_format | Article |
| series | Анналы клинической и экспериментальной неврологии |
| spelling | doaj.art-9f70fc0d48ef4d44961ffd32006ad18f2022-12-22T03:29:32ZengResearch Center of NeurologyАнналы клинической и экспериментальной неврологии2075-54732409-25332017-02-0172395010.17816/psaic236134Current means for identifying the latent stage of a neurodegenerative processS. N. Illarioshkin0A. G. Vlassenko1E. Yu. Fedotova2Research Center of Neurology, Russian Academy of Medical Sciences (Moscow)Department of Radiology, Washington University School of Medicine (St. Louis, MO, USA)Research Center of Neurology, Russian Academy of Medical Sciences (Moscow)A characteristic feature of neurodegenerative diseases is thepresence of a long-term latent stage, while manifestation ofsymptoms occurs after 4060% cells loss in vulnerable neuronpopulations. Therefore, potential for neuroprotection is maximaljust at the latent stage of the process. In this paper, currenttechnologies of presymptomatic diagnosis of the two most commonneurodegenerative disorders, Alzheimers and Parkinsons disease, are presented. On the basis of our own experience anddata from the literature it is shown that neuroimaging methods(identification of beta-amyloid in the brain, or phenomenon ofhyperechogenecity of the s.nigra, etc) in combination with anumber of neurophysiological and molecular/pathobiochemicaltests are principal in revealing persons with high risk of these disorders.Validation of biomarkers under discussion and their integration into uniform diagnostic screening algorithms is at presentone of the most actual fields of neurology.https://annaly-nevrologii.com/journal/pathID/article/viewFile/236/72neurodegenerative diseasesalzheimer’s diseaseparkinson’s diseaselatent stagebiomarkerspopulation screening |
| spellingShingle | S. N. Illarioshkin A. G. Vlassenko E. Yu. Fedotova Current means for identifying the latent stage of a neurodegenerative process Анналы клинической и экспериментальной неврологии neurodegenerative diseases alzheimer’s disease parkinson’s disease latent stage biomarkers population screening |
| title | Current means for identifying the latent stage of a neurodegenerative process |
| title_full | Current means for identifying the latent stage of a neurodegenerative process |
| title_fullStr | Current means for identifying the latent stage of a neurodegenerative process |
| title_full_unstemmed | Current means for identifying the latent stage of a neurodegenerative process |
| title_short | Current means for identifying the latent stage of a neurodegenerative process |
| title_sort | current means for identifying the latent stage of a neurodegenerative process |
| topic | neurodegenerative diseases alzheimer’s disease parkinson’s disease latent stage biomarkers population screening |
| url | https://annaly-nevrologii.com/journal/pathID/article/viewFile/236/72 |
| work_keys_str_mv | AT snillarioshkin currentmeansforidentifyingthelatentstageofaneurodegenerativeprocess AT agvlassenko currentmeansforidentifyingthelatentstageofaneurodegenerativeprocess AT eyufedotova currentmeansforidentifyingthelatentstageofaneurodegenerativeprocess |